In development: Guidance, quality standards and advice
Showing 291 to 297 of 297
| Title | Type | Expected publication date |
|---|---|---|
| Vosoritide for treating achondroplasia in people 4 months and over [ID6488] | Technology appraisal guidance | TBC |
| Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
| Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma ID6672 | Technology appraisal guidance | TBC |
| Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
| Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance | TBC |
| Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance | TBC |